
EyePoint Pharmaceuticals (EYPT) Stock Forecast & Price Target
EyePoint Pharmaceuticals (EYPT) Analyst Ratings
Bulls say
EyePoint is viewed favorably because management reiterated that the DME program remains on track to read out in 4Q27, and the lack of safety red flags from wet AMD supports confidence in the platform’s risk profile. The company’s DURAVYU and Durasert technology could still unlock meaningful value through positive Phase III COMO/CAPRI data, FDA openness to a wet AMD regulatory path based on pooled LUGANO/LUCIA and secondary endpoints, or a strategic partnership. Its outlook is further strengthened by the possibility of non-dilutive financing or cost reductions that could extend cash runway beyond the DME readout, preserving optionality while the pipeline advances.
Bears say
EyePoint is facing a fundamentally weakened investment case because DURAVYU has now missed non-inferiority in both pivotal wet AMD studies, with LUCIA showing a -3.7-letter adjusted treatment difference versus aflibercept and the stock falling 85% at market close after the miss. Management’s plan is still unproven, as wAMD options remain undecided while the company shifts to DME, yet that program carries the same non-inferiority framework and must overcome prior failures in wAMD and NPDR before investors regain confidence. With only $118m in cash and short-term investments, a workforce reduction of about 53%, and runway guided into 4Q27, the shares look likely to stay range-bound amid clinical and regulatory overhang until the 4Q27 readout.
This aggregate rating is based on analysts' research of EyePoint Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
EyePoint Pharmaceuticals (EYPT) Analyst Forecast & Price Prediction
Start investing in EyePoint Pharmaceuticals (EYPT)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About EyePoint Pharmaceuticals (EYPT) Forecast
EyePoint Pharmaceuticals (EYPT) Analyst Forecast & Price Prediction
Start investing in EyePoint Pharmaceuticals (EYPT)
Order type
Buy in
Order amount
Est. shares
0 shares